)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Vaishali Pharma
Vaishali Pharma (VAISHALI) investor relations material
Vaishali Pharma Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary14 Aug, 2026
Executive summary
Board approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, along with the limited review reports from statutory auditors.
Annual Report and Director's Report for FY 2025-26 were approved, and the 19th AGM is scheduled for 24 September 2026 via video conferencing.
Appointment of scrutinizer for remote e-voting at the AGM was confirmed.
Financial highlights
Standalone revenue from operations for Q1 FY27 was ₹2,289.14 lakh, compared to ₹2,374.71 lakh in Q1 FY26 and ₹2,692.71 lakh in Q4 FY26.
Standalone net profit for Q1 FY27 was ₹148.97 lakh, up from ₹127.93 lakh in Q1 FY26 but down from ₹26.64 lakh in Q4 FY26.
Consolidated revenue from operations for Q1 FY27 was ₹2,289.14 lakh, with consolidated net profit at ₹154.54 lakh, including a ₹5.65 lakh share of profit from the associate.
Basic and diluted EPS for Q1 FY27 were ₹0.11 (standalone) and ₹0.12 (consolidated).
Outlook and guidance
No explicit forward-looking guidance provided, but the inclusion of the associate's results from September 2025 is expected to impact future consolidated performance.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vaishali Pharma
- Bad-debt write-offs drove FY20 profit sharply lower as pandemic uncertainty clouded the outlook.VAISHALI
Q4 19/20 - Profit rose despite lower revenue, while receivables, COVID disruption and export growth plans remained pivotal.VAISHALIQ4 20/21
- FY22 profit rose to ₹40.2m as export expansion and margin gains remained key priorities.VAISHALIQ4 21/22
- Profit rose despite lower revenue, while aged receivables cloud recovery.VAISHALIQ4 22/23
- Strong revenue and profit growth, with new associate consolidation and auditor caution on receivables.VAISHALIQ4 25/26
- Q3 FY26 profit rose sequentially, preferential issue to raise ₹12.25 crore approved.VAISHALIQ3 25/26
- Strong revenue and profit growth with improved margins and positive operating cash flow.VAISHALIQ2 25/26
- Q1 FY26 saw higher revenue but lower net profit and EPS amid rising expenses.VAISHALIQ1 25/26
- Q3 FY25 revenue was flat, but net profit fell on higher costs; auditors found no misstatements.VAISHALIQ3 24/25
Next Vaishali Pharma earnings date
Q2 26/2720 Nov, 2026
Vaishali Pharma
Next Vaishali Pharma earnings date
Q2 26/2720 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Vaishali Pharma Limited is a pharmaceutical company involved in the manufacturing, marketing, and export of pharmaceutical formulations, active pharmaceutical ingredients (APIs), surgical products, and nutraceuticals. The company offers a wide range of dosage forms including tablets, capsules, injectables, and ointments across various therapeutic segments. It serves domestic and international markets and engages in contract manufacturing and third-party distribution. Vaishali Pharma Limited operates in compliance with industry quality standards and regulatory requirements. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.